# US 6,730,326 B2 · Thermodynamically stable modification of 1-(4-carbazolyl-oxy-3[2-(2-methoxyphenoxy)-ethylamino]-2-propanol process for its preparation and pharmaceutical compositions containing it

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,326 B2
- Document ID: US6730326B2
- Status: Granted
- Kind: B2
- Application number: 10/166,188
- Filed: 2002-06-10
- Published: 2003-02-20
- Granted: 2004-05-04
- Earliest claimed: 1997-07-22
- Assignees: Roche Diagnostics GmbH
- Inventors: Peter Beyer; Erhard Reinholz
- Web page: https://patentgrep.com/patent/US6730326B2

## CPC

- C07D 209/88: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a thermodynamically stable modification of (±)1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole and pharmacologically acceptable salts or optically active forms thereof as well as processes for their preparation and pharmaceutical compositions containing one or more of them.

## Claims

### Claim 1

A crystalline form of (±)1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole substantially free of other forms, having a melting point of about 123-126° C., the following X-ray diffraction pattern obtained from a CUka radiation at 20=9.5, 10.8, 12.0, 14.5, 19.6, 21.5, 22.3, and an infrared spectrum with a sharp peak at 3451 cm−1, or a pharmaceutically acceptable salt or optically active form thereof.
